Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment

doi:10.12998/wjcc.v9.i21.5812

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3956)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

243

WORD

156

HTML

1728

Figures (1-4)

355

Tables (1-1)

283

Sum=2765

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

322

Download

869

Sum=1191

Jul 26, 2021 (publication date) through Jan 11, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Clin Cases. Jul 26, 2021; 9(21): 5812-5821
Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.5812

Full Size Figure Download Figure

Figure 2 Dynamics during nucleos(t)ide analogue treatment. A: Hepatitis B virus (HBV) DNA; B: Alanine transaminase (ALT); C: Hepatitis B surface antigen (HBsAg); D: Soluble programmed death-1 (sPD-1) levels; soluble programmed death-1; E, F: Levels in patients without (E)/with (F) HBsAg loss at different time points.

Citation: Tan N, Luo H, Kang Q, Pan JL, Cheng R, Xi HL, Chen HY, Han YF, yang YP, Xu XY. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases 2021; 9(21): 5812-5821
URL: https://www.wjgnet.com/2307-8960/full/v9/i21/5812.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i21.5812